Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingGlobeNewsWire • Monday
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAPRNewsWire • 04/12/24
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityGlobeNewsWire • 04/10/24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 03/28/24
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaGlobeNewsWire • 03/26/24
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 03/25/24
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 03/21/24
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024GlobeNewsWire • 03/18/24
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type CGlobeNewsWire • 03/04/24
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/15/24
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of DirectorsGlobeNewsWire • 01/23/24
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type CGlobeNewsWire • 01/08/24
Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical OfficerGlobeNewsWire • 01/04/24
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug AdministrationGlobeNewsWire • 12/27/23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease CompanyGlobeNewsWire • 11/20/23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ETGlobeNewsWire • 10/31/23
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout OctoberGlobeNewsWire • 10/19/23
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACERBusiness Wire • 10/10/23
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and DirectorGlobeNewsWire • 10/10/23
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual MeetingGlobeNewsWire • 10/05/23